The metabolism drugs market comprises pharmaceutical drugs that help regulate metabolic processes in the human body. Some key metabolism drugs include insulin, glucagon-like peptide 1 (GLP-1) agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and others used for treating diabetes, obesity, and other metabolic disorders. These drugs help maintain normal blood sugar levels, aid weight loss, and improve metabolic functions. The global prevalence of metabolic conditions like diabetes and obesity has increased significantly in recent years due to changing lifestyles and dietary patterns. According to the International Diabetes Federation, around 537 million adults lived with diabetes in 2021 worldwide and the number is projected to rise to 783 million by 2045. This rising prevalence of metabolic disorders is a major driver for the growth of the global metabolism drugs market.
The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the metabolism drugs market is the rise in adoption of orally administered drugs over injectables. Traditionally, many metabolism drugs involved injectables like insulin but new oral drugs are gaining popularity due to ease of administration through oral route. For instance, GLP-1 receptor agonists and SGLT2 inhibitors are increasingly prescribed as first-line treatment in type 2 diabetes due to their efficacy and oral formulations. Another notable trend is the emergence of new drug formulations with improved efficacy and safety profiles. Researchers are developing modified release formulations, fixed-dose combinations, and newer drug delivery mechanisms to offer enhanced treatment outcomes. This is expected to drive revenue growth of the metabolism drugs market during the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the metabolism drugs market is moderate as launching new metabolism drugs requires significant investment in R&D and clinical trials. However, specialty pharmacies have low barriers to entry.
Bargaining power of buyers: The bargaining power of buyers is moderate as buyers have several options to choose from major players in the market. However, specialty drugs have niche markets lowering buyer power.
Bargaining power of suppliers: The bargaining power of suppliers is low due to the presence of a large number of raw material suppliers. However, specialty drugs require special raw materials increasing supplier power.
Threat of new substitutes: The threat of new substitutes is low as metabolism disorders require customized drugs with fewer side effects limiting the scope of substitutes.
Competitive rivalry: The competitive rivalry is high among major players to gain more market share through new product launches, expansions, and collaborations.
Key Takeaways
The Global Metabolism Drugs Market Size is expected to witness high growth over the forecast period due to the increasing prevalence of metabolic disorders. The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030.
North America is expected to dominate the global market due to the growing awareness regarding specialty drugs, presence of key players, and developed healthcare infrastructure in the region. Europe is also anticipated to hold a major market share owing to the availability of funds for R&D. This is attributed to the increasing investments by industry players, developed healthcare infrastructure, and rising adoption of specialty drugs to manage metabolic disorders.
Key players: Key players operating in the Metabolism Drugs Market are Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd€TMs Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma. These players are focusing on expanding their product portfolios and geographic reach through collaborations and new launches.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it